Table 3.

Coronary Calcification in women participating in the CEEonly – arm of WHI^a

Number of Participantsc
	CEE n=537	Placebo n = 527	Odds Ratiod (95%CI)
CAC Scores (Agatston Units)
0 (referent)b	299	266	1.00
>0	238	261	0.81 (0.64–1.03)
<10 (referent)b	348	302	1.00
≥ 10	189	225	0.73 (0.57–0.93)
<100 (referent)b	448	408	1.00
≥100	89	119	0.68 (0.50–0.93)
Vasomotor Symptomse
Yes	23.3%	26.5%
No	76.7%	73.5%

^aDerived from Tables 1 and 2 of (Manson et al., 2007).

^bReferent groups are all participants within the stated CAC range.

^cNumbers of individuals who were at least 80% adherent to CEE or placebo for at least 5 years.

^dOdds ratios were calculated for the CEE group compared to the Placebo group.

^ePercentage of women reporting moderate-to-severe vasomotor symptoms in each assigned group prior to initiation of treatment (baseline).